Objective: To evaluate GP regimen alone and GP regimen combined with Kanglaite on the efficacy,side effects and the improvement of quality of life in the treatment of advanced non - small cell lung cancer ( NSCLC ). Methods: Thirty five patients with NSCLC in stage Ⅲ and Ⅳ were treated by GP regimen combining with Kanglaite, and 35 patients were treated with GP regimen alone. Kanglaite was used on the first day of each chemotherapy cycle for consecutive 10 days, and the dosage was 200 ml/d. GP regimen included gemcitabine 1000mg/m2 on 1st and 8th days and cisplatin 25 mg/m2 on 1st to 3rd day. The treatment was repeated every three weeks. The efficacy, side effect and quality of life were compared after two cycles of chemotherapy. Results: Response rate was 42.86％ in combining group and 34.28 ％ in control group( P ＜ 0.05 ) . Quality of life in treat group was significantly higher than that in control group after treatment ( P ＜ 0.05 ). The incidence of side effects in combining group was lower than that in control group, and the degree was also slighter. Conclusion: Kanglaite in combination with GP regimen can be used for the treatment of advanced NSCLC. It can improve efficacy and the quality of life, and reduce the side effect of chemotherapy.%目的:观察康莱特联合GP方案治疗晚期非小细胞肺癌的临床疗效及化疗不良反应.方法:将70 例患者随机分成治疗组、对照组,各35例;两组均采用GP 方案:吉西他滨1000 mg/m2,第1 、8 天,顺铂25 mg/m2,第1-3天,3 周为一周期.治疗组在此基础上于化疗第一天开始加用康莱特200ml静滴连用10天.两个周期化疗结束后比较两组临床疗效、生存质量、不良反应等情况.结果:治疗组近期疗效有效率为42.86%,对照组为34.28%,两组比较有显著性差异(P＜0.05);治疗组KPS评分有效率为68.57%,对照组为42.86%,两组比较有显著性差异(P＜0.05);两组主要不良反应为骨髓抑制及胃肠道反应,但治疗组的反应程度较对照组轻,两组比较有显著性差异(P＜0.05).结论:康莱特联合化疗治疗晚期非小细胞肺癌可提高临床疗效,减轻化疗的不良反应,提高患者生存质量.
展开▼
